Takeda Pharmaceutical Li... (TAK)
15.05
-0.09 (-0.59%)
At close: Mar 28, 2025, 3:59 PM
15.02
-0.20%
After-hours: Mar 28, 2025, 06:43 PM EDT
Takeda Pharmaceutical Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 | FY05 | FY04 | FY03 | FY02 | FY01 | FY00 | FY99 |
| Revenue | 4,263.8B | 4,027.5B | 3,569B | 3,197.8B | 3,291.2B | 2,097.2B | 1,770.5B | 1,732.1B | 1,807.4B | 1,777.8B | 1,691.7B | 1,557.3B | 1,508.9B | 1,419.4B | 1,466B | 1,538.3B | 1,374.8B | 1,305.2B | 1,212.2B | 1,123B | 1,086.4B | 1,046.1B | 1,005.1B | 963.48B | 923.13B |
| Cost of Revenue | 1,431.5B | 1,244.1B | 1,106.8B | 994.31B | 1,089.8B | 659.69B | 495.92B | 558.75B | 535.4B | 520.99B | 490.26B | 447.63B | 433.19B | 317.58B | 285.06B | 289.54B | 278.63B | 279.66B | 282.1B | 279.18B | 269.39B | 300.34B | 337.85B | 384.01B | 432.33B |
| Gross Profit | 2,832.3B | 2,783.4B | 2,462.2B | 2,203.5B | 2,201.4B | 1,437.5B | 1,274.6B | 1,173.3B | 1,272B | 1,256.8B | 1,201.4B | 1,109.6B | 1,075.7B | 1,101.8B | 1,180.9B | 1,248.8B | 1,096.2B | 1,025.5B | 930.11B | 843.78B | 817.04B | 745.74B | 667.21B | 579.47B | 490.8B |
| Operating Income | 214.07B | 490.5B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B | 130.83B | -129.25B | 139.27B | 122.5B | 265.03B | 367.08B | 420.21B | 306.47B | 423.12B | 458.5B | 402.81B | 385.28B | 371.63B | 310.69B | 281.24B | 226.1B | 171.44B |
| Interest Income | 11.29B | 62.91B | 23.7B | 105.52B | 27.83B | 6.62B | 39.54B | 12.27B | 21.64B | 15.36B | 49.3B | 16.3B | 6.3B | 1.73B | 1.98B | 11.38B | 62.06B | 56.24B | 34.21B | 18.1B | 10.9B | 10.13B | 9.61B | 9.93B | n/a |
| Pretax Income | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 94.9B | 217.21B | 143.35B | 120.54B | -145.44B | 158.85B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.1B | 446.14B | 431.9B | 373.43B | 263.08B | 202.76B |
| Net Income | 144.07B | 317.02B | 230.06B | 376B | 44.24B | 109.13B | 186.89B | 114.94B | 80.17B | -145.78B | 106.66B | 131.24B | 124.16B | 247.87B | 297.74B | 234.38B | 355.45B | 335.81B | 313.25B | 277.44B | 285.26B | 271.76B | 235.66B | 146.85B | 119.63B |
| Selling & General & Admin | 1,053.8B | 997.31B | 886.36B | 875.66B | 964.74B | 717.6B | 628.11B | 619.06B | 650.77B | 612.61B | 556.21B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | n/a | n/a | n/a | n/a | n/a | n/a | 385.96B | n/a | 319.36B |
| Research & Development | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.3B | 325.44B | 312.3B | 345.93B | 382.1B | 341.56B | 324.29B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | 834.44B | -9.47B | 588.87B | 1,409.4B | 1,434.3B | 908.87B | 707.38B | 705.13B | 795.22B | 1,004B | 720.59B | 5.81B | n/a | 3.78B | 735M | 12.13B | 673.05B | 567B | 527.3B | 458.5B | 445.4B | 435.05B | n/a | 353.37B | n/a |
| Operating Expenses | 2,618.2B | 2,292.9B | 2,001.3B | 1,694.2B | 2,101B | 1,277.2B | 1,032.8B | 1,017.4B | 1,141.1B | 1,386.1B | 1,062.1B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 673.05B | 567B | 527.3B | 458.5B | 445.4B | 435.05B | 385.96B | 353.37B | 319.36B |
| Interest Expense | 153.63B | 169.7B | 166.61B | 248.63B | 165.01B | 48.16B | 31.93B | 23.25B | 31.93B | 32.88B | 30.72B | 3.32B | 1.88B | 1.33B | 1.43B | 1.62B | 333M | 247M | 365M | 334M | 359M | 420M | 759M | 1.02B | 1.19B |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 113.21B | 105.25B | 175.52B | n/a | 94.52B | 94.01B | 108.1B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 4,049.7B | 3,537B | 3,108.2B | 2,688.5B | 3,190.8B | 1,936.9B | 1,528.7B | 1,576.2B | 1,676.5B | 1,907.1B | 1,552.4B | 1,434.8B | 1,243.9B | 1,052.3B | 1,045.8B | 1,231.9B | 951.68B | 846.67B | 809.4B | 737.68B | 714.8B | 735.39B | 723.82B | 737.38B | 751.69B |
| Income Tax | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.5B | 27.83B | 37.06B | -2.4B | 49.29B | -3.88B | 125.21B | 121.33B | 115.67B | 161.35B | 218.77B | 285.84B | 201.36B | 160.23B | 157.91B | 157.49B | 134.89B | 114.15B | 81.45B |
| Shares Outstanding (Basic) | 1.56B | 1.55B | 1.56B | 1.56B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B |
| Shares Outstanding (Diluted) | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B |
| EPS (Basic) | 92.09 | 204.29 | 147.14 | 240.72 | 28.41 | 69.57 | 239.35 | 147.15 | 102.26 | -92.94 | 135.10 | 188.21 | 157.29 | 314.01 | 377.19 | 289.82 | 418.97 | 386.00 | 353.47 | 313.01 | 321.86 | 307.63 | 267.02 | 166.39 | 135.55 |
| EPS (Diluted) | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 69.57 | 237.55 | 146.26 | 101.71 | -92.94 | 134.95 | 188.17 | 157.26 | 313.96 | 377.14 | 289.80 | 418.97 | 386.00 | 353.47 | 313.01 | 321.86 | 307.63 | 267.02 | 166.39 | 135.55 |
| EBITDA | 874.6B | 1,184.5B | 1,183.2B | 983.72B | 880.33B | 464.22B | 359.96B | 296.88B | 349.85B | 57.29B | 368.18B | 351.18B | 404.56B | 479.63B | 532.08B | 518.25B | 608.87B | 654.45B | 547.05B | 472.66B | 474.59B | 462.28B | 402.62B | 297.7B | 237.32B |
| Depreciation & Amortization | 728B | 664.4B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B | 197.38B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.6B | 33.36B |